Advancements in ovarian cancer immunodiagnostics and therapeutics via phage display technology.
| Autor: | Li Y; Obstetrics and Gynecology Center, First Hospital of Jilin University, Changchun, Jilin, China.; Department of Rehabilitation, School of Nursing, Jilin University, Changchun, China., Li XM; Department of Rehabilitation, School of Nursing, Jilin University, Changchun, China., Yang KD; Department of Rehabilitation, School of Nursing, Jilin University, Changchun, China., Tong WH; Obstetrics and Gynecology Center, First Hospital of Jilin University, Changchun, Jilin, China. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in immunology [Front Immunol] 2024 May 28; Vol. 15, pp. 1402862. Date of Electronic Publication: 2024 May 28 (Print Publication: 2024). |
| DOI: | 10.3389/fimmu.2024.1402862 |
| Abstrakt: | Ovarian cancer, ranking as the seventh most prevalent malignancy among women globally, faces significant challenges in diagnosis and therapeutic intervention. The difficulties in early detection are amplified by the limitations and inefficacies inherent in current screening methodologies, highlighting a pressing need for more efficacious diagnostic and treatment strategies. Phage display technology emerges as a pivotal innovation in this context, utilizing extensive phage-peptide libraries to identify ligands with specificity for cancer cell markers, thus enabling precision-targeted therapeutic strategies. This technology promises a paradigm shift in ovarian cancer management, concentrating on targeted drug delivery systems to improve treatment accuracy and efficacy while minimizing adverse effects. Through a meticulous review, this paper evaluates the revolutionary potential of phage display in enhancing ovarian cancer therapy, representing a significant advancement in combating this challenging disease. Phage display technology is heralded as an essential instrument for developing effective immunodiagnostic and therapeutic approaches in ovarian cancer, facilitating early detection, precision-targeted medication, and the implementation of customized treatment plans. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Li, Li, Yang and Tong.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|